4Hunt SA. ACC/AHA task force on practice guideline ACC/AHA 2005 guideline update for the diagnosis and man of chronic heart failure in the adult[J]. T Am Coll Cardiol,2005,46(6) :82.
1Oishi Y, Ozono R, Yoshizumi M, et al. AT2 receptor mediates the cardioprotective effects of AT1 receptor antagonist in postmyocardial infarction remodeling. Life Sci, 2006, 80(1): 82-88.
2Liu YH, Yang XP, Sharov VG, et al. Effects of angiotensin-converting enzyme inhibitors and angiotensin Ⅱ type 1 receptor in rats with heart failure. Role of kinins and angiotensin Ⅱ type 2 receptors. J Clin Invest, 1997, 99(8) : 1926-1935.
3Pitt B, Segal R, Martinez FA, et al. Randomised trial of losartan versus captopril in patients over 65 with heart failure ( Evaluation Losartan in the Elderly Study, ELITE). Lancet, 1997, 349(9054) : 747-752.
4Pitt B, Poole-Wilson PA, Segal R, et al. Effect of losartan compared with captoprll on mortality in patients with symptomatic heart failure: randomized trial-the Losartan Heart Failure Survival Study ELITE Ⅱ. Lancet, 2000, 355 (9215): 1582-1587.
5Dickstein K, Kjekshus J; OPTIMAAL Steering Committee of the OPTIMAAL Study Group. Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised triaL Optimal Trial in Myocardial Infarction with Angiotensin Ⅱ Antagonist Losartan.Lancet, 2002, 360 (9335) : 752-60.
6Pfeffer MA, McMurray JJ, Velazquez EJ, et al. Valsartan,captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med,2003, 349 (20): 1893-1906.
7Bart BA, Ertl G, Held P, et al. Contemporary management of patients with left ventricular systolic dysfunction. Results from the Study of Patients Intolerant of Converting Enzyme Inhibitors (SPICE) Registry. Eur Heart J, 1999, 20(16) : 1182-1190.
8Granger CB, McMurray JJ, Yusuf S, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. The Lancet, 2003, 362(9386) : 772-776.
9Zisman LS, MeixeU GE, Bristow MR, et al. Angiotensin-(1-7) formation in the intact human heart: in vivo dependence on angiotensin Ⅱ as substrate. Circulation, 2003, 108 (14) : 1679-1681.
10Ferrario CM, Jessup J, ChappeU MC, et al. GaUagher. Effect of angiotensin-converting enzyme inhibition and angiotensin Ⅱ receptor blockers on cardiac angiotensin-converting enzyme 2.Circulation, 2005, 111 (20) : 2605-2610.
